New York, NY, March 14, 2018  -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the presentation of new research highlighting the significant benefits to patient outcomes through individualization of care guided by blood volume analysis (BVA). The study by John E. Strobeck, MD, PhD and Wayne L. Miller, MD, PhD, of the Mayo Clinic appeared during the session entitled “Cardiotoxity, Cardiomyophathies and Heart Failure Readmissions” at the American College of Cardiology 2018 Scientific Session (1105-104). 

-- New Non-GM Wheat Varieties Naturally High in Amylose and Fiber Create Unique Value Opportunities for Consumer Branded Products and Tangible Health Benefits for Consumers --

 

DAVIS, Calif. -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company, today announced that it has achieved two key technology milestones in its High Fiber Resistant Starch (RS) Wheat program. First, through advanced screening and traditional breeding techniques, the company has developed non-transgenic (non-GM) wheat varieties that contain up to 94 percent amylose, the highest levels available. Increased levels of amylose correspond to high levels of resistant starch, which has been proven to deliver significant health benefits. Second, these same wheat varieties deliver levels of total dietary fiber high enough to meet the threshold required by the US Food and Drug Administration for a “Good Source” of fiber or “High in Fiber” designation on consumer packaging.

Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016

Positive Operating and Net Income Reported for the Fourth Quarter

Conference Call Today at 8:30am Eastern Time

 

CAMBRIDGE, Mass., March 05, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2017 and full year 2018 financial guidance.

 

Fourth Quarter 2017 Financial Highlights

Total net revenues increased 41% to $23.4 million compared to $16.5 million in the fourth quarter of 2016; excluding license revenue, net revenue increased 34% to $22.2 million;

Primary Endpoint Achieved – Statistically Significant Improvement in Proportion of Patients Gaining 15 or More Letters in Visual Acuity

All Key Secondary Endpoints Achieved

Clearside to Host Conference Call Today at 8:30 AM Eastern Time

 

ALPHARETTA, Ga., March 05, 2018  -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.